Humira: Assess the response of psoriasis and psoriatic arthritis to Humira and also Assessing the pharmacogenetic association between IL 12B genetic polymorphism (rs3213094) in psoriatic and psoriatic arthritis patients taking Humira.
Study summary
Psoriasis is a skin disorder that is chronic proliferative and inflammatory in nature. Extensor surfaces, scalp, and lumbosacral area are covered in erythematous plaques with silvery scales. The disease can also impair the eyes and joints. It has no cure. Because of their low quality of life, many psoriasis patients experience depression. In addition to the cutaneous manifestations, it is associated with an increased risk of psoriatic arthritis, depression and cardiovascular disease.
Eligibility
Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
Accepted
Inclusion Criteria:
\- Patients having psoriasis diagnosed clinically for at least 6 months and who have a severity grade of severe, defined as a Psoriasis Area and Severity Index (PASI) score greater than 10, and involvement of greater than 10% of the body surface area (BSA) with psoriatic arthritis.
Exclusion Criteria:
* Patients with other autoimmune or inflammatory conditions (e.g., rheumatoid arthritis, lupus).
* Pregnancy and lactation.
* Patients currently undergoing any treatment other than Humira.
* Patients with known genetic disorders affect immune system function.
* Patients were undergoing any treatment other than Humira in the last 6 months.
* Patients with active infections, including tuberculosis or chronic viral infections (e.g., hepatitis B or C, HIV).
* Patients with contraindication to Humira.
* Renal \&Vascular diseases
Primary outcome measure(s)
Treatment of Psoriasis and Psoriatic Arthritis — 3 Months Treatment the patients whom suffering from Psoriasis and Psoriatic arthritis and Assessment of clinical improvement to Humira therapy according to: PASI score into PASI 50: means 50% reduction in PASI score - an acceptable measure of efficacy for secondary endpoints in psoriasis clinical trials PASI 75: means 75% reduction in PASI score - standard efficacy measure used in most psoriasis clinical studies1 PASI 90: means 90% reduction in PASI score (almost clear skin) PASI 100: means Completely clear skin.
Trial sites (1)
Facility
City
Region
Status
Qina University hospital, South Valley University Hospital
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.